The glymphatic system (GS) is a recently discovered waste clearance system in the brain.
Purpose
To evaluate the most promising magnetic resonance imaging (MRI) sequence(s) and the most optimal sequence parameters for glymphatic MRI (gMRI) 4–24 h after administration of gadolinium-based contrast agent (GBCA).
Material and Methods
Multiple literature databases were systematically searched for articles regarding gMRI or MRI of the perilymph in the inner ear until 11 May 2020. All relevant MRI sequence parameters were tabulated for qualitative analysis. Their potential was assessed based on detection of low dose GBCA, primarily measured as signal intensity (SI) ratio.
Results
Thirty articles were included in the analysis. Three-dimensional fluid attenuated inversion recovery (3D-FLAIR), 3D Real Inversion Recovery (3D-Real IR), and multiple 3D T1-weighted gradient echo sequences were used. In perilymph, 3D-FLAIR with a TE of at least 400 ms yielded the highest SIRs. In the qualitative analysis of inner ear studies using 3D-FLAIR, TR was in the range of 4400–10,000 ms, TI 1500–2600 ms, refocusing flip angle (rFA) (range 120°–180°), and echo train length (ETL) 23–173. In the gMRI studies, quantitative analysis was not possible. In the qualitative analysis, 3D-FLAIR was used in the majority (8/12) of the studies, usually with TR 4800–9000 ms, TI 1650–2500 ms, TE 311–561 ms, rFA 90°–120°, and ETL 167–278.
Conclusion
Long TE 3D-FLAIR is the most promising sequence for detection of low-dose GBCA in the GS. Clinical and/or phantom studies on other MRI parameters are needed for further optimization of gMRI.
IliffJJWangMLiaoY, et al.
A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med2012;
4:ra11.
2.
MestreHMoriYNedergaardM.The Brain’s Glymphatic System: Current Controversies. Trends Neurosci 2020;43:458–466.
3.
AlbargothyNJJohnstonDAMacGregor-SharpM, et al.
Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol2018;
136:139–152.
4.
BakkerENBacskaiBJArbel-OrnathM, et al.
Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol Neurobiol2016;
36:181–194.
5.
RasschaertMWellerROSchroederJA, et al.
Retention of gadolinium in brain parenchyma: pathways for speciation, access, and distribution. A critical review. J Magn Reson Imaging 2020;52:1293–1305.
6.
XieLKangHXuQ, et al.
Sleep drives metabolite clearance from the adult brain. Science2013;
342:373–377.
7.
BenvenisteHLiuXKoundalS, et al.
The glymphatic system and waste clearance with brain aging: a review. Gerontology2019;
65:106–119.
8.
RasmussenMKMestreHNedergaardM.The glymphatic pathway in neurological disorders. Lancet Neurol2018;
17:1016–1024.
9.
TaokaTNaganawaS.Glymphatic imaging using MRI. J Magn Reson Imaging2020;
51:11–24.
LancelotE.Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion. Invest Radiol2016;
51:691–700.
12.
BergerFKubik-HuchRANiemannT, et al.
Gadolinium distribution in cerebrospinal fluid after administration of a gadolinium-based MR contrast agent in humans. Radiology2018;
288:703–709.
13.
JostGFrenzelTBoykenJ, et al.
Long-term excretion of gadolinium-based contrast agents: linear versus macrocyclic agents in an experimental rat model. Radiology2019;
290:340–348.
14.
RobertPFingerhutSFactorC, et al.
One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model. Radiology2018;
288:424–433.
15.
BernaertsADe FoerB.Imaging of Meniere Disease. Neuroimaging Clin N Am2019;
29:19–28.
16.
WangemannP.Supporting sensory transduction: cochlear fluid homeostasis and the endocochlear potential. J Physiol2006;
576:11–21.
17.
MoherDLiberatiATetzlaffJ, et al.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med2009;
6:e1000097.
Deike-HofmannKReuterJHaaseR, et al.
Glymphatic pathway of gadolinium-based contrast agents through the brain: overlooked and misinterpreted. Invest Radiol2019;
54:229–237.
20.
NaganawaSNakaneTKawaiH, et al.
Differences in signal intensity and enhancement on mr images of the perivascular spaces in the basal ganglia versus those in white matter. Magn Reson Med Sci2018;
17:301–307.
21.
NaganawaSNakaneTKawaiH, et al.
Gd-based contrast enhancement of the perivascular spaces in the basal ganglia. Magn Reson Med Sci2016;
16:61–65.
22.
NaganawaSYamazakiMKawaiH, et al.
Contrast enhancement of the anterior eye segment and subarachnoid space: detection in the normal state by heavily T2-weighted 3D FLAIR. Magn Reson Med Sci2011;
10:193–199.
23.
OhashiTNaganawaSOgawaE, et al.
Signal intensity of the cerebrospinal fluid after intravenous administration of gadolinium-based contrast agents: strong contrast enhancement around the vein of Labbe. Magn Reson Med Sci2019;
18:194–199.
24.
EidePKRingstadG.Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: A glymphatic magnetic resonance imaging study. J Cereb Blood Flow Metab2018;
39:1355–1368.
25.
JacobsenHHRingstadGJorstadOK, et al.
The human visual pathway communicates directly with the subarachnoid space. Invest Ophthalmol Vis Sci2019;
60:2773–2780.
26.
RingstadGEidePK.Cerebrospinal fluid tracer efflux to parasagittal dura in humans. Nat Commun2020;
11:354.
27.
RingstadGVatneholSASEidePK.Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain2017;
140:2691–2705.
28.
ZhouYCaiJZhangW, et al.
Impairment of the glymphatic pathway and putative meningeal lymphatic vessels in the aging human. Ann Neurol2020;
87:357–369.
29.
JostGFrenzelTLohrkeJ, et al.
Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol2017;
27:2877–2885.
30.
TaokaTJostGFrenzelT, et al.
Impact of the glymphatic system on the kinetic and distribution of gadodiamide in the rat brain: observations by dynamic MRI and effect of circadian rhythm on tissue gadolinium concentrations. Invest Radiol2018;
53:529–534.
31.
EliezerMPoillonGGillibertA, et al.
Comparison of enhancement of the vestibular perilymph between gadoterate meglumine and gadobutrol at 3-Tesla in Meniere’s disease. Diagn Interv Imaging2018;
99:271–277.
32.
LeeJKimESLeeY, et al.
Quantitative analysis of cochlear signal intensity on three-dimensional and contrast-enhanced fluid-attenuated inversion recovery images in patients with Meniere’s disease: Correlation with the pure tone audiometry test. J Neuroradiol2019;
46:307–311.
33.
LiYShaYWangF, et al.
Comprehensive comparison of MR image quality between intratympanic and intravenous gadolinium injection using 3D real IR sequences. Acta Otolaryngol2019;
139:659–664.
34.
NaganawaSKawaiHTaokaT, et al.
Cochlear lymph fluid signal increase in patients with otosclerosis after intravenous administration of gadodiamide. Magn Reson Med Sci2016;
15:308–315.
35.
NaganawaSIshiharaSIwanoS, et al.
Estimation of gadolinium-induced T1-shortening with measurement of simple signal intensity ratio between the cochlea and brain parenchyma on 3D-FLAIR: correlation with T1 measurement by TI scout sequence. Magn Reson Med Sci2010;
9:17–22.
36.
NahmaniSVaussyAHautefortC, et al.
Comparison of enhancement of the vestibular perilymph between variable and constant flip angle-delayed 3D-FLAIR sequences in Meniere disease. AJNR Am J Neuroradiol2020;
41:706–711.
37.
PakdamanMNIshiyamaGIshiyamaA, et al.
Blood-labyrinth barrier permeability in meniere disease and idiopathic sudden sensorineural hearing loss: findings on delayed postcontrast 3D-FLAIR MRI. AJNR Am J Neuroradiol2016;
37:1903–1908.
38.
SanoRTeranishiMYamazakiM, et al.
Contrast enhancement of the inner ear in magnetic resonance images taken at 10 minutes or 4 hours after intravenous gadolinium injection. Acta Otolaryngol2011;
132:241–246.
39.
ShiSZhouFWangW.3D-real IR MRI of Meniere’s disease with partial endolymphatic hydrops. Am J Otolaryngol2019;
40:589–593.
40.
ShiSGuoPWangW.Magnetic resonance imaging of Meniere’s disease after intravenous administration of gadolinium. Ann Otol Rhinol Laryngol2018;
127:777–782.
41.
SuzukiHTeranishiMSoneM, et al.
Contrast enhancement of the inner ear after intravenous administration of a standard or double dose of gadolinium contrast agents. Acta Otolaryngol2011;
131:1025–1031.
42.
TagayaMYamazakiMTeranishiM, et al.
Endolymphatic hydrops and blood-labyrinth barrier in Meniere’s disease. Acta Otolaryngol2011;
131:474–479.
43.
TagayaMTeranishiMNaganawaS, et al.
3 Tesla magnetic resonance imaging obtained 4 hours after intravenous gadolinium injection in patients with sudden deafness. Acta Otolaryngol2010;
130:665–669.
44.
YamazakiMNaganawaSKawaiH, et al.
Gadolinium distribution in cochlear perilymph: differences between intratympanic and intravenous gadolinium injection. Neuroradiology2012;
54:1161–1169.
45.
YamazakiMNaganawaSTagayaM, et al.
Comparison of contrast effect on the cochlear perilymph after intratympanic and intravenous gadolinium injection. AJNR Am J Neuroradiol2011;
33:773–778.
46.
FreezeWMTer WeeleDNPalmWM, et al.
Optimal detection of subtle gadolinium leakage in CSF with heavily T2-weighted fluid-attenuated inversion recovery imaging. AJNR Am J Neuroradiol2019;
40:1481–1483.
47.
KatoYBokuraKTaokaT, et al.
Increased signal intensity of low-concentration gadolinium contrast agent by longer repetition time in heavily T2-weighted-3D-FLAIR. Jpn J Radiol2019;
37:431–435.
48.
NaganawaSKawaiHSoneM, et al.
Increased sensitivity to low concentration gadolinium contrast by optimized heavily T2-weighted 3D-FLAIR to visualize endolymphatic space. Magn Reson Med Sci2010;
9:73–80.
49.
Attye A. Personal communication. Discontinuing acquisition 3D-real IR. to: Brink W, 2020.
50.
NaganawaS. Gd deposition: How does Gd enter the brain, when BBB is intact? ISMRM presentation. Nagoya:
Nagoya University Graduate School of Medicine,
Department of Radiology, 2017.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
